Napolitano Gennaro, Johnson Jennifer L, He Jing, Rocca Celine J, Monfregola Jlenia, Pestonjamasp Kersi, Cherqui Stephanie, Catz Sergio D
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
EMBO Mol Med. 2015 Feb;7(2):158-74. doi: 10.15252/emmm.201404223.
Metabolite accumulation in lysosomal storage disorders (LSDs) results in impaired cell function and multi-systemic disease. Although substrate reduction and lysosomal overload-decreasing therapies can ameliorate disease progression, the significance of lysosomal overload-independent mechanisms in the development of cellular dysfunction is unknown for most LSDs. Here, we identify a mechanism of impaired chaperone-mediated autophagy (CMA) in cystinosis, a LSD caused by defects in the cystine transporter cystinosin (CTNS) and characterized by cystine lysosomal accumulation. We show that, different from other LSDs, autophagosome number is increased, but macroautophagic flux is not impaired in cystinosis while mTOR activity is not affected. Conversely, the expression and localization of the CMA receptor LAMP2A are abnormal in CTNS-deficient cells and degradation of the CMA substrate GAPDH is defective in Ctns(-/-) mice. Importantly, cysteamine treatment, despite decreasing lysosomal overload, did not correct defective CMA in Ctns(-/-) mice or LAMP2A mislocalization in cystinotic cells, which was rescued by CTNS expression instead, suggesting that cystinosin is important for CMA activity. In conclusion, CMA impairment contributes to cell malfunction in cystinosis, highlighting the need for treatments complementary to current therapies that are based on decreasing lysosomal overload.
溶酶体贮积症(LSDs)中的代谢物积累会导致细胞功能受损和多系统疾病。尽管底物减少和降低溶酶体过载的疗法可以改善疾病进展,但对于大多数LSDs而言,溶酶体过载非依赖性机制在细胞功能障碍发展中的意义尚不清楚。在此,我们在胱氨酸病中鉴定出伴侣介导的自噬(CMA)受损的机制,胱氨酸病是一种由胱氨酸转运蛋白胱氨酸转运体(CTNS)缺陷引起的LSD,其特征是胱氨酸在溶酶体中积累。我们发现,与其他LSDs不同,胱氨酸病中自噬体数量增加,但巨自噬通量未受损,而mTOR活性不受影响。相反,在CTNS缺陷细胞中,CMA受体LAMP2A的表达和定位异常,并且在Ctns(-/-)小鼠中CMA底物GAPDH的降解存在缺陷。重要的是,半胱胺治疗尽管减少了溶酶体过载,但并未纠正Ctns(-/-)小鼠中存在缺陷的CMA或胱氨酸病细胞中LAMP2A的错误定位,而通过CTNS表达可挽救这种情况,这表明胱氨酸转运体对CMA活性很重要。总之,CMA受损导致胱氨酸病中的细胞功能障碍,这突出表明需要采用与目前基于降低溶酶体过载的疗法互补的治疗方法。